Results 11 to 20 of about 143,360 (302)
JACC: Case Reports, 2021 We present a case of transcatheter heart valve thrombosis in a 76-year-old man with paroxysmal atrial fibrillation on therapeutic anticoagulation with apixaban and polycythemia vera.
Gauranga Mahalwar, MD +6 more
doaj +1 more source
Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding
Perspectives in Clinical Research, 2023 Background: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation.
Anitta Shaji +4 more
doaj +1 more source
Antiplatelets in Stroke Prevention [PDF]
Current Vascular Pharmacology, 2014 Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death ...
Antonio, Pinto +4 more
openaire +3 more sources
Journal of The Arab Society for Medical Research, 2023 Platelets play a major role in normal hemostatic and thrombotic processes. Aggregation of platelets presents the key pathophysiological step in the development of cardiovascular diseases; hence, antiplatelet agents remain crucial in the treatment of cardiovascular diseases. They may target the three principal phases leading to
Asma Haffouz +2 more
openaire +2 more sources
Foods, 2023 Increasing evidence has shown collagen hydrolysate involves a variety of bioactivities. In our previous study, multiple antiplatelet peptides containing Hyp/Pro-Gly were identified in collagen hydrolysates from Salmo salar and silver carp skin and ...
Yijie Yang, Qi Tian, Shiming Li, Bo Li
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background The optimal antiplatelet strategy for patients with acute coronary syndromes who require coronary artery bypass surgery remains unclear. While a more potent antiplatelet regimen will predispose to perioperative bleeding, it is hypothesized ...
Kiran Sarathy +8 more
doaj +1 more source
Antiplatelets and Anticoagulants [PDF]
Clinical Cardiology, 2010 AbstractThose of us who see patients with cardiovascular disorders frequently use antiplatelet and anticoagulant agents; the common agents are aspirin, clopidogrel, and warfarin. This editorial is a personal viewpoint about commonly used drugs, not so commonly used drugs, and drugs that are yet to be used clinically. Copyright © 2010 Wiley Periodicals,
openaire +2 more sources
Antiplatelets and Anticoagulants in Vitreoretinal Surgery: A Systematic Review
Life, 2023 Background: Antiplatelets and anticoagulants have substantially influenced contemporary vitreoretinal surgical practices. The availability of new oral blood thinners has recently spurred a renewed interest in the clinical approach to vitreoretinal ...
Filippo Confalonieri +7 more
doaj +1 more source
Ticagrelor versus clopidogrel in the management of acute myocardial infarction
Journal of Community Hospital Internal Medicine Perspectives, 2019 Hypothesis: In the care of acute myocardial infarction, ticagrelor attenuates post-ischemic myocardial damage and inhibits platelet activity to a greater extent than clopidogrel.
Candice Volney +2 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017 BackgroundPrior Studies have suggested better outcomes in smokers compared with nonsmokers receiving clopidogrel (“smoker's paradox”). The impact of a more intensive clopidogrel regimen on ischemic and bleeding risks in smokers with acute coronary ...
Matthias Bossard +13 more
doaj +1 more source